1 Study Coverage 1.1 Anaplastic Astrocytoma Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Introduction 1.2 Global Anaplastic Astrocytoma Outlook 2017 VS 2022 VS 2028 1.2.1 Global Anaplastic Astrocytoma Market Size for the Year 2017-2028 1.2.2 Global Anaplastic Astrocytoma Market Size for the Year 2017-2028 1.3 Anaplastic Astrocytoma Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Anaplastic Astrocytoma in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Anaplastic Astrocytoma Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Anaplastic Astrocytoma Market Dynamics 1.4.1 Anaplastic Astrocytoma Industry Trends 1.4.2 Anaplastic Astrocytoma Market Drivers 1.4.3 Anaplastic Astrocytoma Market Challenges 1.4.4 Anaplastic Astrocytoma Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Anaplastic Astrocytoma by Type 2.1 Anaplastic Astrocytoma Market Segment by Type 2.1.1 Temodar 2.1.2 Temozolomide 2.1.3 Matulane 2.1.4 Procarbazine 2.1.5 Others 2.2 Global Anaplastic Astrocytoma Market Size by Type (2017, 2022 & 2028) 2.3 Global Anaplastic Astrocytoma Market Size by Type (2017-2028) 2.4 United States Anaplastic Astrocytoma Market Size by Type (2017, 2022 & 2028) 2.5 United States Anaplastic Astrocytoma Market Size by Type (2017-2028) 3 Anaplastic Astrocytoma by Application 3.1 Anaplastic Astrocytoma Market Segment by Application 3.1.1 Pre-Registration Phase 3.1.2 Clinical Trail Phase 3.2 Global Anaplastic Astrocytoma Market Size by Application (2017, 2022 & 2028) 3.3 Global Anaplastic Astrocytoma Market Size by Application (2017-2028) 3.4 United States Anaplastic Astrocytoma Market Size by Application (2017, 2022 & 2028) 3.5 United States Anaplastic Astrocytoma Market Size by Application (2017-2028) 4 Global Anaplastic Astrocytoma Competitor Landscape by Company 4.1 Global Anaplastic Astrocytoma Market Size by Company 4.1.1 Top Global Anaplastic Astrocytoma Companies Ranked by Revenue (2021) 4.1.2 Global Anaplastic Astrocytoma Revenue by Player (2017-2022) 4.2 Global Anaplastic Astrocytoma Concentration Ratio (CR) 4.2.1 Anaplastic Astrocytoma Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Anaplastic Astrocytoma in 2021 4.2.3 Global Anaplastic Astrocytoma Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Anaplastic Astrocytoma Headquarters, Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Type 4.3.1 Global Anaplastic Astrocytoma Headquarters and Area Served 4.3.2 Global Anaplastic Astrocytoma Companies Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Anaplastic Astrocytoma Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Anaplastic Astrocytoma Market Size by Company 4.5.1 Top Anaplastic Astrocytoma Players in United States, Ranked by Revenue (2021) 4.5.2 United States Anaplastic Astrocytoma Revenue by Players (2020, 2021 & 2022) 5 Global Anaplastic Astrocytoma Market Size by Region 5.1 Global Anaplastic Astrocytoma Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Anaplastic Astrocytoma Market Size by Region (2017-2028) 5.2.1 Global Anaplastic Astrocytoma Market Size by Region: 2017-2022 5.2.2 Global Anaplastic Astrocytoma Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Anaplastic Astrocytoma Market Size YoY Growth 2017-2028 6.1.2 North America Anaplastic Astrocytoma Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Anaplastic Astrocytoma Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Anaplastic Astrocytoma Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Anaplastic Astrocytoma Market Size YoY Growth 2017-2028 6.3.2 Europe Anaplastic Astrocytoma Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Anaplastic Astrocytoma Market Size YoY Growth 2017-2028 6.4.2 Latin America Anaplastic Astrocytoma Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Anaplastic Astrocytoma Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Anaplastic Astrocytoma Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 UAE 7 Company Profiles 7.1 Genentech 7.1.1 Genentech Company Details 7.1.2 Genentech Business Overview 7.1.3 Genentech Anaplastic Astrocytoma Introduction 7.1.4 Genentech Revenue in Anaplastic Astrocytoma Business (2017-2022) 7.1.5 Genentech Recent Development 7.2 Isarna Therapeutics 7.2.1 Isarna Therapeutics Company Details 7.2.2 Isarna Therapeutics Business Overview 7.2.3 Isarna Therapeutics Anaplastic Astrocytoma Introduction 7.2.4 Isarna Therapeutics Revenue in Anaplastic Astrocytoma Business (2017-2022) 7.2.5 Isarna Therapeutics Recent Development 7.3 Axelar 7.3.1 Axelar Company Details 7.3.2 Axelar Business Overview 7.3.3 Axelar Anaplastic Astrocytoma Introduction 7.3.4 Axelar Revenue in Anaplastic Astrocytoma Business (2017-2022) 7.3.5 Axelar Recent Development 7.4 Pfizer 7.4.1 Pfizer Company Details 7.4.2 Pfizer Business Overview 7.4.3 Pfizer Anaplastic Astrocytoma Introduction 7.4.4 Pfizer Revenue in Anaplastic Astrocytoma Business (2017-2022) 7.4.5 Pfizer Recent Development 7.5 Amgen 7.5.1 Amgen Company Details 7.5.2 Amgen Business Overview 7.5.3 Amgen Anaplastic Astrocytoma Introduction 7.5.4 Amgen Revenue in Anaplastic Astrocytoma Business (2017-2022) 7.5.5 Amgen Recent Development 7.6 Novartis 7.6.1 Novartis Company Details 7.6.2 Novartis Business Overview 7.6.3 Novartis Anaplastic Astrocytoma Introduction 7.6.4 Novartis Revenue in Anaplastic Astrocytoma Business (2017-2022) 7.6.5 Novartis Recent Development 7.7 Avid Bioservices 7.7.1 Avid Bioservices Company Details 7.7.2 Avid Bioservices Business Overview 7.7.3 Avid Bioservices Anaplastic Astrocytoma Introduction 7.7.4 Avid Bioservices Revenue in Anaplastic Astrocytoma Business (2017-2022) 7.7.5 Avid Bioservices Recent Development 7.8 EirGen Pharma 7.8.1 EirGen Pharma Company Details 7.8.2 EirGen Pharma Business Overview 7.8.3 EirGen Pharma Anaplastic Astrocytoma Introduction 7.8.4 EirGen Pharma Revenue in Anaplastic Astrocytoma Business (2017-2022) 7.8.5 EirGen Pharma Recent Development 7.9 Boehringer Ingelheim 7.9.1 Boehringer Ingelheim Company Details 7.9.2 Boehringer Ingelheim Business Overview 7.9.3 Boehringer Ingelheim Anaplastic Astrocytoma Introduction 7.9.4 Boehringer Ingelheim Revenue in Anaplastic Astrocytoma Business (2017-2022) 7.9.5 Boehringer Ingelheim Recent Development 7.10 Celldex Therapeutics 7.10.1 Celldex Therapeutics Company Details 7.10.2 Celldex Therapeutics Business Overview 7.10.3 Celldex Therapeutics Anaplastic Astrocytoma Introduction 7.10.4 Celldex Therapeutics Revenue in Anaplastic Astrocytoma Business (2017-2022) 7.10.5 Celldex Therapeutics Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Anaplastic Astrocytoma Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Anaplastic Astrocytoma Market Trends Table 3. Anaplastic Astrocytoma Market Drivers Table 4. Anaplastic Astrocytoma Market Challenges Table 5. Anaplastic Astrocytoma Market Restraints Table 6. Global Anaplastic Astrocytoma Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Anaplastic Astrocytoma Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Anaplastic Astrocytoma Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Anaplastic Astrocytoma Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Anaplastic Astrocytoma Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Anaplastic Astrocytoma Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Anaplastic Astrocytoma Revenue Share by Player, 2017-2022 Table 13. Global Anaplastic Astrocytoma Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Anaplastic Astrocytoma by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anaplastic Astrocytoma as of 2021) Table 15. Top Players of Anaplastic Astrocytoma in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Anaplastic Astrocytoma Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Anaplastic Astrocytoma Players in United States Market, Ranking by Revenue (2021) Table 20. United States Anaplastic Astrocytoma Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Anaplastic Astrocytoma Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Anaplastic Astrocytoma Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Anaplastic Astrocytoma Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Anaplastic Astrocytoma Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Anaplastic Astrocytoma Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Anaplastic Astrocytoma Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Anaplastic Astrocytoma Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Anaplastic Astrocytoma Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Anaplastic Astrocytoma Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Genentech Company Details Table 31. Genentech Business Overview Table 32. Genentech Anaplastic Astrocytoma Product Table 33. Genentech Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Table 34. Genentech Recent Development Table 35. Isarna Therapeutics Company Details Table 36. Isarna Therapeutics Business Overview Table 37. Isarna Therapeutics Anaplastic Astrocytoma Product Table 38. Isarna Therapeutics Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Table 39. Isarna Therapeutics Recent Development Table 40. Axelar Company Details Table 41. Axelar Business Overview Table 42. Axelar Anaplastic Astrocytoma Product Table 43. Axelar Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Table 44. Axelar Recent Development Table 45. Pfizer Company Details Table 46. Pfizer Business Overview Table 47. Pfizer Anaplastic Astrocytoma Product Table 48. Pfizer Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Table 49. Pfizer Recent Development Table 50. Amgen Company Details Table 51. Amgen Business Overview Table 52. Amgen Anaplastic Astrocytoma Product Table 53. Amgen Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Table 54. Amgen Recent Development Table 55. Novartis Company Details Table 56. Novartis Business Overview Table 57. Novartis Anaplastic Astrocytoma Product Table 58. Novartis Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Table 59. Novartis Recent Development Table 60. Avid Bioservices Company Details Table 61. Avid Bioservices Business Overview Table 62. Avid Bioservices Anaplastic Astrocytoma Product Table 63. Avid Bioservices Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Table 64. Avid Bioservices Recent Development Table 65. EirGen Pharma Company Details Table 66. EirGen Pharma Business Overview Table 67. EirGen Pharma Anaplastic Astrocytoma Product Table 68. EirGen Pharma Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Table 69. EirGen Pharma Recent Development Table 70. Boehringer Ingelheim Company Details Table 71. Boehringer Ingelheim Business Overview Table 72. Boehringer Ingelheim Anaplastic Astrocytoma Product Table 73. Boehringer Ingelheim Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Table 74. Boehringer Ingelheim Recent Development Table 75. Celldex Therapeutics Company Details Table 76. Celldex Therapeutics Business Overview Table 77. Celldex Therapeutics Anaplastic Astrocytoma Product Table 78. Celldex Therapeutics Revenue in Anaplastic Astrocytoma Business (2017-2022) & (US$ Million) Table 79. Celldex Therapeutics Recent Development Table 80. Research Programs/Design for This Report Table 81. Key Data Information from Secondary Sources Table 82. Key Data Information from Primary Sources List of Figures Figure 1. Anaplastic Astrocytoma Product Picture Figure 2. Global Anaplastic Astrocytoma Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Anaplastic Astrocytoma Market Size 2017-2028 (US$ Million) Figure 4. United States Anaplastic Astrocytoma Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Anaplastic Astrocytoma Market Size 2017-2028 (US$ Million) Figure 6. United States Anaplastic Astrocytoma Market Share in Global 2017-2028 Figure 7. Anaplastic Astrocytoma Report Years Considered Figure 8. Product Picture of Temodar Figure 9. Product Picture of Temozolomide Figure 10. Product Picture of Matulane Figure 11. Product Picture of Procarbazine Figure 12. Product Picture of Others Figure 13. Global Anaplastic Astrocytoma Market Share by Type in 2022 & 2028 Figure 14. Global Anaplastic Astrocytoma Market Size by Type (2017-2028) & (US$ Million) Figure 15. Global Anaplastic Astrocytoma Market Share by Type (2017-2028) Figure 16. United States Anaplastic Astrocytoma Market Share by Type in 2022 & 2028 Figure 17. United States Anaplastic Astrocytoma Market Size by Type (2017-2028) & (US$ Million) Figure 18. United States Anaplastic Astrocytoma Market Share by Type (2017-2028) Figure 19. Product Picture of Pre-Registration Phase Figure 20. Product Picture of Clinical Trail Phase Figure 21. Global Anaplastic Astrocytoma Market Share by Application in 2022 & 2028 Figure 22. Global Anaplastic Astrocytoma Market Size by Application (2017-2028) & (US$ Million) Figure 23. Global Anaplastic Astrocytoma Market Share by Application (2017-2028) Figure 24. United States Anaplastic Astrocytoma Market Share by Application in 2022 & 2028 Figure 25. United States Anaplastic Astrocytoma Market Size by Application (2017-2028) & (US$ Million) Figure 26. United States Anaplastic Astrocytoma Market Share by Application (2017-2028) Figure 27. North America Anaplastic Astrocytoma Market Size Growth Rate 2017-2028 (US$ Million) Figure 28. U.S. Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 29. Canada Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 30. Europe Anaplastic Astrocytoma Market Size Growth Rate 2017-2028 (US$ Million) Figure 31. Germany Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 32. France Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. U.K. Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. Italy Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Russia Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 36. Asia-Pacific Anaplastic Astrocytoma Market Size Growth Rate 2017-2028 (US$ Million) Figure 37. China Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 38. Japan Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. South Korea Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. India Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. Australia Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Taiwan Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Indonesia Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Thailand Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Malaysia Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. Philippines Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Latin America Anaplastic Astrocytoma Market Size Growth Rate 2017-2028 (US$ Million) Figure 48. Mexico Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 49. Brazil Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Argentina Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Middle East & Africa Anaplastic Astrocytoma Market Size Growth Rate 2017-2028 (US$ Million) Figure 52. Turkey Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 53. Saudi Arabia Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. UAE Anaplastic Astrocytoma Market Size Growth Rate (2017-2028) & (US$ Million) Figure 55. Genentech Revenue Growth Rate in Anaplastic Astrocytoma Business (2017-2022) Figure 56. Isarna Therapeutics Revenue Growth Rate in Anaplastic Astrocytoma Business (2017-2022) Figure 57. Axelar Revenue Growth Rate in Anaplastic Astrocytoma Business (2017-2022) Figure 58. Pfizer Revenue Growth Rate in Anaplastic Astrocytoma Business (2017-2022) Figure 59. Amgen Revenue Growth Rate in Anaplastic Astrocytoma Business (2017-2022) Figure 60. Novartis Revenue Growth Rate in Anaplastic Astrocytoma Business (2017-2022) Figure 61. Avid Bioservices Revenue Growth Rate in Anaplastic Astrocytoma Business (2017-2022) Figure 62. EirGen Pharma Revenue Growth Rate in Anaplastic Astrocytoma Business (2017-2022) Figure 63. Boehringer Ingelheim Revenue Growth Rate in Anaplastic Astrocytoma Business (2017-2022) Figure 64. Celldex Therapeutics Revenue Growth Rate in Anaplastic Astrocytoma Business (2017-2022) Figure 65. Bottom-up and Top-down Approaches for This Report Figure 66. Data Triangulation Figure 67. Key Executives Interviewed

Genentech Isarna Therapeutics Axelar Pfizer Amgen Novartis Avid Bioservices EirGen Pharma Boehringer Ingelheim Celldex Therapeutics